Novel targets for antidepressant therapies

Paul E. Holtzheimer, Charles Nemeroff

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Most depressed patients fail to achieve remission despite adequate antidepressant monotherapy, and a substantial minority show minimal improvement despite optimal and aggressive therapy. However, major advances have taken place in elucidating the neurobiology of depression, and several novel targets for antidepressant therapy have emerged. Three primary approaches are currently being taken: 1) optimizing the pharmacologic modulation of monoaminergic neurotransmission, 2) developing medications that target neurotransmitter systems other than the monoamines, and 3) directly modulating neuronal activity via focal brain stimulation. We review novel therapeutic targets for developing improved antidepressant therapies, including triple monoamine reuptake inhibitors, atypical antipsychotic augmentation, dopamine receptor agonists, corticotropin-releasing factor-1 receptor antagonists, glucocorticoid receptor antagonists, substance P receptor antagonists,N-methyl-d-aspartate receptor antagonists, nemifitide, omega-3 fatty acids, and melatonin receptor agonists. Developments in therapeutic focal brain stimulation include vagus nerve stimulation, transcranial magnetic stimulation, magnetic seizure therapy, transcranial direct current stimulation, and deep brain stimulation.

Original languageEnglish
Pages (from-to)465-473
Number of pages9
JournalCurrent Psychiatry Reports
Volume10
Issue number6
DOIs
StatePublished - Dec 1 2008
Externally publishedYes

Fingerprint

Antidepressive Agents
Therapeutics
Neurokinin-1 Receptor Antagonists
Melatonin Receptors
Vagus Nerve Stimulation
Deep Brain Stimulation
Neurobiology
Transcranial Magnetic Stimulation
Dopamine Agonists
Glucocorticoid Receptors
Omega-3 Fatty Acids
Brain
Synaptic Transmission
Antipsychotic Agents
Neurotransmitter Agents
Seizures
Depression

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Novel targets for antidepressant therapies. / Holtzheimer, Paul E.; Nemeroff, Charles.

In: Current Psychiatry Reports, Vol. 10, No. 6, 01.12.2008, p. 465-473.

Research output: Contribution to journalArticle

Holtzheimer, Paul E. ; Nemeroff, Charles. / Novel targets for antidepressant therapies. In: Current Psychiatry Reports. 2008 ; Vol. 10, No. 6. pp. 465-473.
@article{0ad79cb478054a21b4fd5b04ff34abd3,
title = "Novel targets for antidepressant therapies",
abstract = "Most depressed patients fail to achieve remission despite adequate antidepressant monotherapy, and a substantial minority show minimal improvement despite optimal and aggressive therapy. However, major advances have taken place in elucidating the neurobiology of depression, and several novel targets for antidepressant therapy have emerged. Three primary approaches are currently being taken: 1) optimizing the pharmacologic modulation of monoaminergic neurotransmission, 2) developing medications that target neurotransmitter systems other than the monoamines, and 3) directly modulating neuronal activity via focal brain stimulation. We review novel therapeutic targets for developing improved antidepressant therapies, including triple monoamine reuptake inhibitors, atypical antipsychotic augmentation, dopamine receptor agonists, corticotropin-releasing factor-1 receptor antagonists, glucocorticoid receptor antagonists, substance P receptor antagonists,N-methyl-d-aspartate receptor antagonists, nemifitide, omega-3 fatty acids, and melatonin receptor agonists. Developments in therapeutic focal brain stimulation include vagus nerve stimulation, transcranial magnetic stimulation, magnetic seizure therapy, transcranial direct current stimulation, and deep brain stimulation.",
author = "Holtzheimer, {Paul E.} and Charles Nemeroff",
year = "2008",
month = "12",
day = "1",
doi = "10.1007/s11920-008-0075-5",
language = "English",
volume = "10",
pages = "465--473",
journal = "Current Psychiatry Reports",
issn = "1523-3812",
publisher = "Current Science, Inc.",
number = "6",

}

TY - JOUR

T1 - Novel targets for antidepressant therapies

AU - Holtzheimer, Paul E.

AU - Nemeroff, Charles

PY - 2008/12/1

Y1 - 2008/12/1

N2 - Most depressed patients fail to achieve remission despite adequate antidepressant monotherapy, and a substantial minority show minimal improvement despite optimal and aggressive therapy. However, major advances have taken place in elucidating the neurobiology of depression, and several novel targets for antidepressant therapy have emerged. Three primary approaches are currently being taken: 1) optimizing the pharmacologic modulation of monoaminergic neurotransmission, 2) developing medications that target neurotransmitter systems other than the monoamines, and 3) directly modulating neuronal activity via focal brain stimulation. We review novel therapeutic targets for developing improved antidepressant therapies, including triple monoamine reuptake inhibitors, atypical antipsychotic augmentation, dopamine receptor agonists, corticotropin-releasing factor-1 receptor antagonists, glucocorticoid receptor antagonists, substance P receptor antagonists,N-methyl-d-aspartate receptor antagonists, nemifitide, omega-3 fatty acids, and melatonin receptor agonists. Developments in therapeutic focal brain stimulation include vagus nerve stimulation, transcranial magnetic stimulation, magnetic seizure therapy, transcranial direct current stimulation, and deep brain stimulation.

AB - Most depressed patients fail to achieve remission despite adequate antidepressant monotherapy, and a substantial minority show minimal improvement despite optimal and aggressive therapy. However, major advances have taken place in elucidating the neurobiology of depression, and several novel targets for antidepressant therapy have emerged. Three primary approaches are currently being taken: 1) optimizing the pharmacologic modulation of monoaminergic neurotransmission, 2) developing medications that target neurotransmitter systems other than the monoamines, and 3) directly modulating neuronal activity via focal brain stimulation. We review novel therapeutic targets for developing improved antidepressant therapies, including triple monoamine reuptake inhibitors, atypical antipsychotic augmentation, dopamine receptor agonists, corticotropin-releasing factor-1 receptor antagonists, glucocorticoid receptor antagonists, substance P receptor antagonists,N-methyl-d-aspartate receptor antagonists, nemifitide, omega-3 fatty acids, and melatonin receptor agonists. Developments in therapeutic focal brain stimulation include vagus nerve stimulation, transcranial magnetic stimulation, magnetic seizure therapy, transcranial direct current stimulation, and deep brain stimulation.

UR - http://www.scopus.com/inward/record.url?scp=58449114465&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58449114465&partnerID=8YFLogxK

U2 - 10.1007/s11920-008-0075-5

DO - 10.1007/s11920-008-0075-5

M3 - Article

VL - 10

SP - 465

EP - 473

JO - Current Psychiatry Reports

JF - Current Psychiatry Reports

SN - 1523-3812

IS - 6

ER -